Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Metformin in PCOS
NCT06142656Phase 3Recruiting
- Sponsor
- October 6 University
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of vildagliptin in polycystic ovary syndrome (PCOS) (2 arms), sponsored by October 6 University. Primary endpoints: Luteinizing Hormone Concentration at 3 months, Follicle-Stimulating Hormone Concentration at 3 months and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
vildagliptin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT06142656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06142656.